CAS: 37836-90-1
Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
---|---|---|---|---|
1-(7-Methoxy-4-methylquinazolin-2-yl)guanidine REF: IN-DA01JX4TCAS: 37836-90-1 | 98% | 55,00 €~479,00 € | Mar 10 Dic 24 | |
MPO-IN-28 REF: TM-T5340CAS: 37836-90-1 | 99.02% | 40,00 €~615,00 € | Vie 13 Dic 24 | |
1-(7-Methoxy-4-methylquinazolin-2-yl)guanidine REF: 10-F545366CAS: 37836-90-1 | 98.0% | A consultar | Lun 16 Dic 24 | |
MPO-IN-28 REF: 3D-MBA83690CAS: 37836-90-1 | Min. 95% | A consultar | Vie 17 Ene 25 |
1-(7-Methoxy-4-methylquinazolin-2-yl)guanidine
CAS:37836-90-1
Fórmula:
C11H13N5O
Pureza:
98%
Forma y color:
Solid
Peso molecular:
231.2538
Ref: IN-DA01JX4T
5mg | 55,00 € | ||
10mg | 69,00 € | ||
25mg | 118,00 € | ||
50mg | 188,00 € | ||
100mg | 213,00 € | ||
250mg | 479,00 € |
Entrega estimada en Estados Unidos, el Martes 10 de Diciembre de 2024
MPO-IN-28
CAS:37836-90-1
MPO-IN-28 is a novel potent, irreversible Myeloperoxidase (MPO) inhibitor with IC50 of 44 nM.
Fórmula:
C11H13N5O
Pureza:
99.02%
Forma y color:
Solid
Peso molecular:
231.25
Ref: TM-T5340
1mg | 40,00 € | ||
2mg | 52,00 € | ||
5mg | 78,00 € | ||
10mg | 119,00 € | ||
25mg | 186,00 € | ||
50mg | 279,00 € | ||
100mg | 425,00 € | ||
200mg | 615,00 € | ||
1mL*10mM (DMSO) | 158,00 € |
Entrega estimada en Estados Unidos, el Viernes 13 de Diciembre de 2024
1-(7-Methoxy-4-methylquinazolin-2-yl)guanidine
CAS:37836-90-1
Pureza:
98.0%
Peso molecular:
231.25900268554688
Ref: 10-F545366
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar | ||
100mg | A consultar | ||
250mg | A consultar |
Entrega estimada en Estados Unidos, el Lunes 16 de Diciembre de 2024
MPO-IN-28
CAS:37836-90-1
MPO-IN-28 is a specific inhibitor of myeloperoxidase (MPO) and has shown to be efficacious in …
Fórmula:
C11H13N5O
Pureza:
Min. 95%
Peso molecular:
231.25 g/mol
Ref: 3D-MBA83690
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar | ||
100mg | A consultar |
Entrega estimada en Estados Unidos, el Viernes 17 de Enero de 2025